Absorption Systems, of Exton, Pa., appointed Albert Owen vice president, strategic planning.

Affymax Inc., of Palo Alto, Calif., appointed Daniel Levitt chief operating officer and head of research and development.

Albany Molecular Research Inc., of Albany, N.Y., added Brian Russell as senior director, human resources; Barbara Galbiati as section head, analytical services; and Lioudmila Tchistiakova as section head, microbiology and genomics. Also, it promoted Bruce Sargent to director of medicinal chemistry and elected Paul Anderson to its board.

Caprion Pharmaceuticals Inc., of Montreal, added Daniel Chelsky as executive vice president and chief scientific officer.

Cardiome Pharma Corp., of Vancouver, British Columbia, appointed Alan Moore executive vice president of clinical development and regulatory affairs.

Cephalon Inc., of West Chester, Pa., appointed Gail Wilensky to its board.

ComGenex Inc., of Budapest, Hungary, added Derek Reynolds to its scientific advisory board.

Corus Pharma Inc., of Seattle, appointed Donald Seaton chief financial officer.

Deltagen Inc., of Redwood City, Calif., appointed Geoffrey Yarranton executive vice president of research and development.

Dendreon Corp., of Seattle, promoted Mitchell Gold to chief business officer and Deborah Elvins to vice president of legal affairs.

Genencor International Inc., of Palo Alto, Calif., hired Thomas Rathjen as vice president of investor relations.

Genset SA, of Paris, appointed Hiroaki Tanaka vice president of bioinformatics; John Lucas vice president, intellectual property; Denis Ravel head of the San Diego Research Center; and Malcolm Bates general counsel.

Genta Inc., of Berkeley Heights, N.J., appointed Bharat Mehta vice president, manufacturing operations.

GlycoGenesys Inc., of Boston, added Christopher Szustkiewicz as senior vice president, operations and development.

Human Genome Sciences Inc., of Rockville, Md., added Gilles Gallant as vice president, oncology.

Inhibitex Inc., of Atlanta, hired Seth Hetherington as vice president of clinical affairs and chief medical officer and David Wonnacott as vice president, quality and regulatory affairs.

InterMune Inc., of Brisbane, Calif., appointed Lawrence Blatt and Brian Murphy to vice president of biopharmacology research, and director, clinical research, hepatitis, respectively.

La Jolla Pharmaceutical Co., of San Diego, appointed Kenneth Heilbrunn vice president of clinical development.

Magellan Pharmaceutical Development, of Research Triangle Park, N.C., named Lori Feehan vice president of business development.

Maxim Pharmaceuticals Inc., of San Diego, promoted Pam Gleason to vice president, human resources; named Dale Sander vice president, corporate development; and named John Prunty treasurer and assistant corporate secretary.

MorphoSys AG, of Martinsried, Germany, appointed Daniel Camus to its supervisory board.

Neurogen Corp., of Branford, Conn., added Edmund Harrigan as executive vice president and chief development officer and promoted Alan Hutchison to executive vice president, discovery research.

Panacea Pharmaceuticals Inc., of Rockville, Md., appointed Dean Lewis chief financial officer.

Pharmacopeia Inc., of Princeton, N.J., appointed John Hanlon executive vice president and chief financial officer.

Pharmos Corp., of Iselin, N.J., appointed Lawrence Marshall to its board.

Psychiatric Genomics Inc., of Gaithersburg, Md., appointed Bradley Lorimier to its board.

QLT Inc., of Vancouver, British Columbia, appointed Bill Newell senior vice president and chief business officer.

Rubicon Genomics Inc., of Ann Arbor, Mich., formed a scientific advisory board consisting of new members Michael Boehnke, Anthony Czarnik and Bruce Roe.

SangStat Medical Corp., of Fremont, Calif., added Rayasam Prasad as senior vice president of worldwide regulatory affairs and compliance.

Seattle Genetics Inc., of Bothell, Wash., appointed Douglas Southern to its board and chairman of its audit committee.

Sprout Group, of New York, appointed James Niedel venture partner for health care technology investments.

Sygen International plc, of Berkeley, Calif., appointed Michael Bailey chief information officer.

Symyx Technologies Inc., of Santa Clara, Calif., added Irving Rappaport as vice president, intellectual property licensing business.

The National Center for Genome Resources, of Santa Fe, N.M., added Geert Wenes to its bioinformatics department as program leader.

Third Wave Technologies Inc., of Madison, Wis., added Lori Lehman as vice president of business development for its genomics unit and David Nuti as corporate controller. Also, it appointed Donagh McCarthy senior vice president and general manager and added Jack Orville as director of sales, both for its clinical business unit.

Tm Bioscience Corp., of Toronto, elected Paul Lucas to its board.